TVTX Q2 2020 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$48M+8.3% YoY

Gross Profit

$47M96.9% margin

Operating Income

-$23M-47.7% margin

Net Income

-$26M-53.8% margin

EPS (Diluted)

$-0.58

QoQ Revenue Growth

+1.4%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$11M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$679M

Total Liabilities

$360M

Stockholders' Equity

$319M

Cash & Equivalents

$237M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$48M	$45M	+8.3%
Gross Profit	$47M	$44M	+7.3%
Operating Income	-$23M	-$37M	+36.7%
Net Income	-$26M	-$39M	+32.6%

Revenue Segments

Tiopronin Products

$27M55%

Bile Acid Products

$22M45%